A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects (Limsafe)

Trial Profile

A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects (Limsafe)

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs Imiquimod (Primary)
  • Indications Actinic keratosis; Basal cell cancer; Genital warts
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Apr 2012 Status changed from active, no longer recruiting to completed according to a Moberg Derma media release.
    • 02 Apr 2012 New source identified and integrated (ClinicalTrials.gov record NCT01567683).
    • 02 Apr 2012 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top